Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 3/20 | 0.62 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.62 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16129417 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL18746352 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL10070674 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL18746353 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL18387240 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL18383020 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL10298049 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL16900305 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL18387241 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL13895786 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9474687-B2 | Combination peptide-nanoparticles and delivery systems incorporating same | MONOSOL RX, LLC (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150190476-A1 | NANOPARTICLE FILM DELIVERY SYSTEMS | MONOSOL RX, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150099698-A1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2015-04-09 | — | — | US | disclosed |
| US-8974826-B2 | Nanoparticle film delivery systems | MONOSOL RX, LLC (US) | 2015-03-10 | — | — | US | disclosed |
| US-8790704-B2 | Combination peptide-nanoparticles and delivery systems incorporating same | MONOSOL RX, LLC (US) | 2014-07-29 | — | — | US | disclosed |
| US-20120301535-A1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | AQUESTIVE THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120009260-A1 | NANOPARTICLE FILM DELIVERY SYSTEMS | AQUESTIVE THERAPEUTICS, INC. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099698-A1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | CALCA, LNPEP, IAPP | LGALS8 260/4885LGALS3 156/4885LGALS4 196/4885 |
| US-20120009260-A1 | NANOPARTICLE FILM DELIVERY SYSTEMS | CD63, DSTN, EPCAM | LGALS8 878/4885LGALS3 369/4885LGALS4 1202/4885 |
| US-20150190476-A1 | NANOPARTICLE FILM DELIVERY SYSTEMS | CD63, DSTN, EPCAM | LGALS8 878/4885LGALS3 369/4885LGALS4 1202/4885 |
| US-20120301535-A1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | CALCA, LNPEP, IAPP | LGALS8 260/4885LGALS3 156/4885LGALS4 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.